REFI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
REFI is not a good buy right now for an impatient investor. The chart trend is still bearish (weak momentum and bearish moving-average stack), and there are no Intellectia buy signals to justify forcing an entry today. While insider buying and a bullish open-interest put/call ratio are positives, the latest quarter showed clear YoY declines in revenue, earnings, and EPS, which reduces near-term upside conviction.
Trend/Momentum: Bearish. SMA_200 > SMA_20 > SMA_5 indicates a sustained downtrend. MACD histogram (-0.00945) is below zero and negatively expanding, suggesting downside momentum is still building rather than stabilizing. RSI: RSI_6 at 36.76 is weak and nearing oversold territory, which can support a short-term bounce, but it is not yet a confirmed reversal signal. Key levels: Pivot 12.426 is the near-term line to reclaim. Immediate support is S1 12.181 (then S2 12.03). Resistance is R1 12.67 (then R2 12.821). With price at 12.255, it is sitting just above support; a break below ~12.18 increases risk of slipping toward ~12.03. Pattern-based forward look: Similar-pattern stats imply modest upside over a month (+3.72%) but limited edge in the next day/week.
Intellectia Proprietary Trading Signals
Insider activity: Insiders are Buying, with buying amount up ~6632.92% over the last month—often a supportive signal near depressed prices.
Options positioning: Bullish open-interest skew (put/call 0.45).
Analyst stance: Oppenheimer maintains Outperform with a $14 target, implying upside from ~$12.
Technical bounce potential: Price is near support (12.
with a weak/low RSI that can precede short reflex rallies.
Downtrend intact: Bearish moving averages and worsening MACD histogram argue against a clean, immediate reversal.
Fundamental deceleration: Latest quarter showed YoY declines in revenue, net income, and EPS.
No near-term news catalysts: No notable news/events in the last week to force a sentiment shift.
Options are expensive (high IV percentile): If the stock doesn’t move up soon, option buyers face higher premium decay; this can also reflect elevated uncertainty.
Latest quarter: 2025/Q3. Growth trend: Weak/declining YoY. Revenue fell to 15,250,866 (-6.20% YoY), Net Income fell to 8,934,539 (-20.31% YoY), and EPS fell to 0.42 (-25.00% YoY). Gross margin improved to 89.73 (+0.90% YoY), but profitability in absolute dollars and per-share terms deteriorated, which is a negative setup for near-term multiple expansion.
Recent change: On 2025-11-06, Oppenheimer lowered the price target to $14 from $16 after quarterly results while reiterating Outperform. Wall Street pros vs cons (from provided data): Pros: Still-rated Outperform with meaningful upside to PT; insider buying supports confidence. Cons: PT cut signals reduced expectations after results; fundamentals (revenue/earnings/EPS) are trending down YoY, aligning with the bearish technical setup. Politician/influential trading: No recent congress trading data available (no evidence of political buying/selling from the provided dataset).
